Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection

Huang,Ming‑Yii; Huang,Chun‑Ming; Tsai,Hsiang‑Lin; Huang,Ching‑Wen; Hsieh,Hui‑Min; Yeh,Yung‑Sung; Wu,Jeng‑Yih; Wang,Wen‑Ming; Wang,Jaw‑Yuan

doi:10.3892/ol.2017.7073

Comparison of adjuvant FOLFOX4 chemotherapy and oral UFUR/LV following adjuvant FOLFOX4 chemotherapy in patients with stage III colon cancer subsequent to radical resection

Authors:
- Ming‑Yii Huang
- Chun‑Ming Huang
- Hsiang‑Lin Tsai
- Ching‑Wen Huang
- Hui‑Min Hsieh
- Yung‑Sung Yeh
- Jeng‑Yih Wu
- Wen‑Ming Wang
- Jaw‑Yuan Wang
View Affiliations

Affiliations: Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of General Surgery Medicine, Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Department of Public Health, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Colorectal Surgery, Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
Published online on: September 26, 2017 https://doi.org/10.3892/ol.2017.7073
Pages: 6754-6762

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to demonstrate the potential advantage of oral uracil‑tegafur (UFUR)/leucovorin (LV) as the subsequent therapy in patients with stage III colon cancer following adjuvant LV, 5‑fluorouracil and oxaliplatin (FOLFOX4) chemotherapy. Of a total 143 patients, 62 patients received only FOLFOX adjuvant chemotherapy (FOLFOX4 biweekly x 12 cycles for 6 months), and 81 patients received FOLFOXU adjuvant treatment (which consisted of FOLFOX4 biweekly x 12 cycles for 6 months followed by oral UFUR/LV for an additional 6 months). The 3‑year disease‑free survival (DFS) rate of the FOLFOXU group was 74.3%; which was superior to that of the FOLFOX4 group (59.9%). The average DFS time of the FOLFOXU group was superior to that of the FOLFOX4 group (P=0.003). The 5‑year overall survival (OS) rate of the FOLFOXU group was 76.9%, which was also superior to that of the FOLFOX4 group (63.8%). The average OS time of patients in the FOLFOXU group was longer than that of the patients in the FOLFOX4 group (hazard ratio, 0.155; 95% confidence interval, 0.054‑0.450; P=0.001). In comparison to the FOLFOX regimen, the FOLFOXU regimen achieved a more favorable response and survival time without a significant increase of toxicities in patients with stage III colon cancer as the adjuvant chemotherapy.

View Figures

View References

1	Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide. IARC CancerBase no. 11, Lyon. 2013.
2	Pestana C, Reitemeier RJ, Moertel CG, Judd ES and Dockerty MB: The natural history of carcinoma of the colon and rectum. Am J Surg. 108:826–829. 1964. View Article : Google Scholar : PubMed/NCBI
3	Falterman KW, Hill CB, Markey JC, Fox JW and Cohn I Jr: Cancer of the colon, rectum, and anus: A review of 2313 cases. Cancer. 34 Suppl:S951–S959. 1974. View Article : Google Scholar
4	Olson RM, Perencevich NP, Malcolm AW, Chaffey JT and Wilson RE: Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer. 45:2969–2974. 1980. View Article : Google Scholar : PubMed/NCBI
5	Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 322:352–358. 1990. View Article : Google Scholar : PubMed/NCBI
6	Ha GS, Kim YW, Choi EH and Kim IY: Factors associated with the lack of adjuvant chemotherapy following curative surgery for stage II and III colon cancer: A Korean National Cohort Study. Anticancer Res. 37:915–922. 2017. View Article : Google Scholar : PubMed/NCBI
7	Bos AC, van Erning FN, van Gestel YR, Creemers GJ, Punt CJ, van Oijen MG and Lemmens VE: Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer. 51:2553–2561. 2015. View Article : Google Scholar : PubMed/NCBI
8	No authors listed: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 345:939–944. 1995.PubMed/NCBI
9	Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med. 122:321–326. 1995. View Article : Google Scholar : PubMed/NCBI
10	O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 16:295–300. 1998. View Article : Google Scholar : PubMed/NCBI
11	Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 11:1879–1887. 1993. View Article : Google Scholar : PubMed/NCBI
12	NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 264:1444–1450. 1990. View Article : Google Scholar : PubMed/NCBI
13	Peters GJ, Van der Wilt CL, van Groeningen CJ, Smid K, Meijer S and Pinedo HM: Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J Clin Oncol. 12:2035–2042. 1994. View Article : Google Scholar : PubMed/NCBI
14	Kelsen DP, Saltz L, Cohen AM, Yao TJ, Enker W, Tong W, Tao Y and Bertino JR: A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer. 74:2224–2233. 1994. View Article : Google Scholar : PubMed/NCBI
15	Department of Health, the Executive Yuan, . Cancer registry annual report. Taiwan, Republic of China: 2012
16	International Union Against Cancer, . TNM classification of malignant tumors. Sobin LH and Wittekind C: 6th. Wiley-Liss Inc; New York: 2002
17	Fleshman JW, Nelson H, Peters WR, Kim HC, Larach S, Boorse RR, Ambroze W, Leggett P, Bleday R, Stryker S, et al: Early results of laparoscopic surgery for colorectal cancer. Retrospective analysis of 372 patients treated by Clinical Outcomes of Surgical Therapy (COST) study group. Dis Colon Rectum. 39 10 Suppl:S53–S58. 1996. View Article : Google Scholar : PubMed/NCBI
18	Franklin ME Jr, Rosenthal D, Abrego-Medina D, Dorman JP, Glass JL, Norem R and Diaz A: Prospective comparison of open vs. laparoscopic colon surgery for carcinoma. Five-year results. Dis Colon Rectum. 39 10 Suppl:S35–S46. 1996. View Article : Google Scholar : PubMed/NCBI
19	Bokey EL, Moore JW, Chapuis PH and Newland RC: Morbidity and mortality following laparoscopic-assisted right hemicolectomy for cancer. Dis Colon Rectum. 39 10 Suppl:S24–S28. 1996. View Article : Google Scholar : PubMed/NCBI
20	Schwenk W, Bohm B and Müller JM: Postoperative pain and fatigue after laparoscopic or conventional colorectal resections. A prospective randomized trial. Surg Endosc. 12:1131–1136. 1998. View Article : Google Scholar : PubMed/NCBI
21	André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
22	Twelves C, Wong A, Nowacki MP, Abt M, Burris H III, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
23	Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV and Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol. 23:8671–8678. 2005. View Article : Google Scholar : PubMed/NCBI
24	Panettiere FJ, Goodman PJ, Costanzi JJ, Cruz AB Jr, Vaitkevicius VK, McCracken JD, Brownlee RW, Laufman L, Stephens RL, Bonnet J, et al: Adjuvant therapy in large bowel adenocarcinoma: Long-term results of a Southwest Oncology Group Study. J Clin Oncol. 6:947–954. 1988. View Article : Google Scholar : PubMed/NCBI
25	Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
26	André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F and de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kurihara M, Uchida J, Fujioka A, Kato T, Ohshimo H, Abe M, Takeda S and Fukushima M: Effect of combination therapy with UFT plus cisplatin (UFTP) on the survival of mice in the experimental model for wide-spread metastasis in the peritoneal cavity of gastrointestinal cancer using colon 26 PMF-15 cells. Anticancer Res. 17:2217–2220. 1997.PubMed/NCBI
28	Smith RE, Lembersky BC, Wieand HS, Colangelo L and Mamounas EP: UFT/leucovorin vs 5-FU/leucovorin in colon cancer. Oncology (Williston Park). 14 10 Suppl 9:S24–S27. 2000.
29	Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 12:2296–2300. 1994. View Article : Google Scholar : PubMed/NCBI
30	Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S and Leichman LP: A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer. 75:782–785. 1995. View Article : Google Scholar : PubMed/NCBI
31	Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M and Creaven PJ: A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 37:581–586. 1996. View Article : Google Scholar : PubMed/NCBI
32	Mukai M, Moriya H, Himeno S, Oida Y, mukohyama S, Nishi T, Nakasaki H, Satoh S and Makuuchi H: Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: Report of two cases. Oncol Rep. 8:1079–1083. 2001.PubMed/NCBI
33	West HJ and Jin JO: JAMA oncology patient page. Performance status in patients with cancer. JAMA Oncol. 1:9982015. View Article : Google Scholar : PubMed/NCBI
34	U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. 2009.